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ScienceDirectReactive multi-target fragments, old synthetic
antimycobacterials that are activated inside Mycobacterium
tuberculosis bacilli and are smaller than the usual drug-like,
single-target molecules, represent critical components of
current tuberculosis chemotherapies. Recent studies showed
that para-aminosalicylic acid is recognized as a substrate by
dihydropteroate synthase and poisons the downstream folate
pathway. Pyrazinamide, a key relapse-reducing drug, is
metabolized by an amidase and the reaction product interferes
with trans-translation, membrane potential and other targets.
However, the mechanism of action of pyrazinamide remains ill-
defined and needs to be understood to rationally approach
treatment shortening. The success of small dirty drugs and
prodrugs suggests that fragment-based whole cell screens
should be re-introduced in our current antimycobacterial drug
discovery efforts.
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Current TB chemotherapies and drug
discovery approaches
Mycobacterium tuberculosis remains the most deadly bac-
terial pathogen globally [1]. Tuberculosis (TB) is treated
with a combination therapy consisting of isoniazid (INH),
rifampicin (RIF), pyrazinamide (PZA), and ethambutol
for 2 months, followed by 4 months of treatment with
INH and RIF. This lengthy regimen has of course
implementation and compliance issues, and this in turn
fuels development of drug resistant disease [2,3]. Multi-
drug resistant TB, defined as being resistant to INH and
RIF, is treated with less potent and more toxic second line
drugs, fluoroquinolones and injectables (aminoglycosides
and capreomycin), and requires at least 2 years of therapy.www.sciencedirect.com Additional drugs include ethionamide (ETH) and para-
aminosalicylic (PAS) [4]. New drugs with new mechanism
of action are urgently needed to shorten the lengthy
treatment regimen of drug susceptible TB and to improve
the poor cure rates of drug resistant disease [5].
Current drug discovery strategies are largely based on
Paul Ehrlich’s magic bullet ‘one drug–one target’ con-
cept. This facilitates lead optimization as it allows simple
structure activity relationships and the use of target-
compound co-structure guided design [6]. A few years
ago, after a decade of biochemical high throughput
screening against genetically validated targets, the anti-
mycobacterial discovery field largely moved back to phe-
notypic whole cell screens to identify compounds with
antimicrobial activity first, then deconvolute the target for
lead optimization [7]. This strategic shift is due to the
large scale failure of target-based approaches: translating
biochemical enzyme inhibitors into whole cell active
antimicrobials turned out to be far more difficult than
anticipated [8]. A key issue is the mycobacterial cell
envelope, representing a formidable permeability barrier
[9]. Target based approaches also fail to capture prodrugs,
which are critical components of anti-TB regimens. It is
to note that both target-first and compound-first avenues
use the same concept: identify single-target, high affinity
(nM) binders, which are non-reactive to avoid side
effects. Other recent approaches do not start with screen-
ing of compound libraries, but make use of existing
antibacterials that either do not work against M. tubercu-
losis, or are not used for treatment of TB. These include
elegant remodelling of antibiotics, such as spectinomycin
[10], to make them stay inside the bacillus (prevent
efflux), and re-purposing of old drugs, such as clofazimine
[11]. High attrition rates, that is, limited success in all
approaches, call for a multipronged ‘leaving no stone
unturned’ strategy [12]. Can we find additional hit-finding
avenues at the bottom of the barrel, approaches that we
have overlooked or not fully utilized so far?
Some of the key TB drugs, discovered in the middle of
the past century by whole cell or animal model screening,
are dirty fragments: they hit multiple targets and their
molecular weights are in the range of 100–300 g/mol
(Figure 1). The fragments are metabolized inside the
tubercle bacillus and only then, after being ‘activated’,
exert their antimicrobial activity [13,14]. This type of
mechanism of action (MoA), polypharmacology, and phy-
sicochemical properties, ‘extra’ small and reactive, is at
odds with main stream antibacterial drug discovery:
attractive leads for medicinal chemistry should inhibitCurrent Opinion in Microbiology 2014, 21:7–12
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Structures of TB fragment drugs. Isoniazid [INH, MW 137], ethionamide [ETH, MW 166], para-aminosalicylic acid [PAS, MW 153] and pyrazinamide
[PZA, MW 123] in comparison with a more standard-sized synthetic drug, moxifloxacin [MXF, MW 402], and a huge natural product, rifampicin [RIF,
MW 823]. MW: molecular weights in g/mol.a single target (to facilitate lead optimization), have a
decent size (to bind a target with high affinity), and should
not be reactive (to avoid side effects) [15].
Can we learn something from these old TB fragment
drugs? Should we start screening again for these types of
compounds to identify leads for the discovery of new TB
drugs? Here we give an update on some recent develop-
ments in our understanding of the MoA of some of these
unusual antibiotics, revealing new concepts and targets.
Then we zoom into a critical sterilizing (relapse-prevent-
ing) TB drug: pyrazinamide (PZA). We argue that the
MoA of this metabolized fragment drug remains an
enigma, despite some recent progress, and that it is
important to identify its targets if we are to eliminate
persisters and substantially shorten TB therapy.
We review some key findings from the past few years.
However, in the case of PZA, we need to go back to theCurrent Opinion in Microbiology 2014, 21:7–12 early 1900s, for some apparently forgotten papers. We
propose that including, or re-introducing, fragment-based
whole cell screens against replicating and dormant bac-
teria in our current approaches to TB drug discovery will
deliver the next generation of TB drugs.
MoA of reactive TB fragment drugs and why it
is useful to understand them
Reactive multi-target fragment drugs, unusually small anti-
mycobacterials that are activated inside the bacilli,
represent critical components of TB chemotherapies
(Figure 1). INH is the key bactericidal (i.e. sputum
count-reducing) fragment drug in the first line regimen
[16]. The compound is oxidized by the bacterial catalase-
peroxidase KatG [17], and its reactive metabolite forms
adducts with NAD(P). The enoyl acyl carrier protein
reductase InhA, required for synthesis of outer-membrane
mycolic acids, appears to be its major target [18]. Additionalwww.sciencedirect.com
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ketoacyl acyl carrier protein synthase KasA [20]. At least 16
other INH adduct-binding mycobacterial proteins as well
as several additional known and unknown INH resistant
mutations extend the target/MoA list [21,22]. ETH, less
well studied, is activated by the mono-oxygenase EthA [23]
and again curiously appears to inhibit InhA as its major
target [24]. More recently, the (first?) MoA of PAS was
determined. The molecule is a structural analogue of the
substrate for dihydropteroate synthase (DHPS) in the
folate pathway of mycobacteria. Therefore it was assumed
that PAS acts as a competitive inhibitor of this enzyme.
However, this is inconsistent with enzymology studies, in
which PAS showed relatively weak inhibitory activity
against DHPS. Elegant metabolomics and genetic analyses
revealed that, rather than being (only) an inhibitor of
DHPS, PAS is recognized as its substrate, resulting in
poisoning of downstream enzymes of the folate pathway,
including dihydrofolate reductase DHFR [25,26]. The
identification of the MoA of INH, ETH and PAS opens the
way for new drug discovery approaches employing those
new chemically validated targets. In the case of INH, for
instance InhA can be directly targeted, circumventing
resistance due to loss of function mutations in the activating
enzyme KatG [27]. In the case of ETH, efforts are under
way to inhibit the repressor (EthR) of expression of the
activating enzyme EthA [28]. This increases the level of
the activating enzyme and perhaps allows lowering the
ETH dose to reduce side effects. The concept of pathway
poisoning revealed by the PAS findings might be
applicable to other biochemical pathways. For the folate
pathway specifically, targets (for instance DHFR) inhibited
by metabolized PAS might be employed for target-directed
design approaches [25,26]. This shows that understand-
ing the MoA of fragments does deliver new concepts and
targets which can be exploited for drug discovery.
The pyrazinamide enigma and why we need to
elucidate it
Shortening treatment time while improving relapse rates
is the major objective in TB drug development [5]. To
reach that goal, understanding why current therapies
must be administered for 6–24 months and more, while
most antimycobacterials — with the exception of
PZA — inhibit and/or kill bacteria in vitro rather rapidly,
is a key starting point. Many working hypotheses, falling
mostly into two categories, have been developed to
explain treatment duration. The drugs may fail to reach
their cellular target, the bacilli, which are hiding in deep
tissue inside various, some poorly vascularized, lesion
types [29]. Alternatively, subpopulations of in vivo bacilli
might be physiologically different from in vitro growing
bacteria, against which we test our compounds. They
could exist in phenotypically drug resistant, for instance
non-replicating, forms [9,30,31]. There is limited evi-
dence to support the pharmacokinetic (PK) and thewww.sciencedirect.com bacteriological models of persistence, but so far we do
not have clear, clinical answers.
What we know is that inclusion of PZA in the current first
line regimen many decades ago resulted in shortening of
treatment from nine to six months. PZA is also considered
a key sterilizing and relapse-preventing drug [32], indi-
cating that it must target persisting mycobacterial popu-
lations that are not killed by other drugs. Thus, learning
from PZA’s mechanism of action, unique treatment short-
ening properties, and lesion penetration characteristics,
seems to be the logical path to rationally discover drugs
that shorten TB therapy. It may also help characterize key
functions of persisting mycobacteria and refine the envi-
ronment or assay conditions adopted in screening cam-
paigns. While we know that M. tuberculosis undergoes
metabolic remodelling and physiological adaptation in
response to microenvironments present in TB lesions
[9], adequate recapitulation of these conditions for
high-throughput screening against persisters is mostly
matter for debate. Defining conditions under which
PZA kills in vitro as it does in vivo would provide much
needed fresh approaches to TB drug discovery. Ironically,
PZA is probably the least understood fragment drug.
What is known about the MoA of PZA? Clinical and in
vitro resistance is largely caused by mutations in the
nicotinamidase gene pncA [33]. The amidase generates
what appears to be the active component pyrazinoic acid
(POA). POA/PZA has multiple MoAs. Under acidic cul-
ture conditions the weak acid POA affects the bacterial
membrane potential [34]. POA (and PZA) inhibits fatty
acid synthase (FAS) I [35–37]. Via an affinity purification
approach, several POA binding proteins were identified,
and it was shown that POA interferes with trans-trans-
lation, a bacterial rescue mechanism for ribosomes stuck
during translation, by binding to the ribosomal S1 protein
[38]. Recently, mutations in the aspartate decarboxylase
PanD, required for synthesis of pantothenate, were found
to correlate with PZA resistance [39]. The identity of
other PncA wild type but PZA resistant mutants remains
to be determined, suggesting additional targets and MoAs
of PZA [39]. It is to note that attempts to isolate POA
resistant tubercle bacilli directly in vitro were unsuccess-
ful [35,40]. Assuming that POA is indeed the critical
antimicrobial metabolite, this suggests that work remains
to be done to unravel the complete MoA of PZA.
A major hurdle in further elucidating PZA’s MoA is the
uncertainty around the predictive value of in vitro culture
conditions under which we measure PZA’s antimicrobial
activity. This makes target deconvolution difficult at best.
PZA was discovered due to its activity in mice [41,42]
rather than in a test tube under standard conditions. Soon
the compound was found to be clinically efficacious [43],
which led to renewed attempts to identify in vitro
conditions under which it was active. In the 1950s,
McDermott and Tompsett showed that PZA exhibitsCurrent Opinion in Microbiology 2014, 21:7–12
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Why fragments might make good TB drugs — a model. A cartoon of a
mycobacterial cell is shown. A (hypothetical) fragment S easily
penetrates the outer membrane via porins. Inside the cytoplasm this
promiscuous binder interferes with multiple targets (B, C). As
promiscuous substrate, S is also metabolized by enzyme A to product P.
P could be chemically reactive (indicated by *) or not, and interferes
again with multiple targets (D, E). Chemically reactive P* could affect
targets directly, and/or after reacting with cellular metabolites. Targets
B, C, D, and E are components of interconnected homeostatic networks,
indicated by the red box. Coincidental ‘correct’ modulation of those
network points by S and P cause irreversible network corruption,
resulting in system collapse and cell death.better growth inhibitory activity in vitro under mildly acid
conditions (while standard media have neutral pH) [44].
This led to the belief that TB lesions are acidic, at least in
localized areas, providing a rational explanation for the
surprising activity of PZA in vivo [32,45]. However, some
early — apparently forgotten — experimental data on the
pH of TB lesions from 1934, suggest that lesions are
actually not acidic [46,47]. In fact, the growth inhibition
data of McDermott and Tompsett do not show that PZA
is active only under acid conditions. They reveal a
U-shaped pH activity curve, where potency decreases
from acidic to neutral pH and then increases again under
mild alkaline conditions [44]. Is our in vitro culture assay
adequate, does it reflect in vivo conditions? Have we been
chasing a PZA-pH myth for the past half century?
In our opinion, two approaches that have been neglected
thus far would help unravel the PZA enigma: first, careful
and standardized measurement of the actual pH of necro-
tic lesions, across animal models and man, and second,
isolation of POA resistant mutants to understand the dirty
drug characteristics of PZA and how they relate to its
sterilizing properties.
Why fragment-based whole cell screens might
be useful
Fragments came to fame in modern drug discovery due to a
novel, fragment-based screening approach against molecu-
lar targets [48]. This method for lead finding makes use of
small libraries of promiscuous binders: very small mol-
ecules (‘fragments’), with weak binding affinities. Bio-
physical and structural biology methods are employed to
identify such high mM/mM binders to a particular target.
The weak binders are then extended or combined to
develop tight, target-specific, high affinity (nM) com-
pounds. Fragments usually represent attractive starting
points for medicinal chemistry as they have preferred
physicochemical and PK properties: they are relatively
small (<300 g/mol) and rather hydrophilic (clogP < 3)
and thus combine attractive water solubility with good
absorption and tissue distribution [48,49].
We have seen that fragments, such as INH and PZA
which are also pro-drugs, identified in the early days of
drug discovery against whole cells (or even in animals) are
among the best TB drugs. Thus being promiscuous and
hitting multiple targets might be an attractive property for
antimycobacterials. Why is that? East and Silver propose
that many successful antibiotics do actually interfere with
multiple targets, they act through polypharmacology,
they are dirty drugs [50]. Could it be that at least some
of these compounds work so well because they modulate
multiple critical points in the metabolic and information
networks that make up a bacterium, and are thus less
prone to rapid emergence of resistance and more likely to
cause irreversible system corruption, collapse and cell
death [51,52]? Due to their small size, fragments are evenCurrent Opinion in Microbiology 2014, 21:7–12 more promiscuous than the larger standard antibiotics
[53]. Furthermore, promiscuously binding fragments
are more likely to be accepted as substrate analogues
(i.e. be promiscuous substrates) and metabolized by the
bacterium, again a property that seems to make good
antimicrobials for TB — perhaps by generating more
molecular diversity, thus allowing interference with even
more targets inside the cell [21] (Figure 2).
Being small and moderately lipophilic is critical in achiev-
ing in vivo exposure and tissue penetration, usually a major
hurdle during lead optimization [6]. In the case of
M. tuberculosis, these physicochemical properties likely
have a positive impact on cellular PK: fragments might
more easily penetrate the mycobacterial cell envelope.
Like Gram-negative bacteria, mycobacteria possess an
outer membrane, but with a unique and quite imperme-
able mycolic acid layer [54]. Cell penetration is thus a major
issue, as reflected by the frustrating disconnect between
activity of hits identified against molecular targets and
against whole cells [15], as well as the low hit rates obtained
in whole cell screens of conventional libraries against
M. tuberculosis compared to Gram positive bacteria (which
lack an outer membrane). While porins, the channels
spanning the outer membrane, prefer small hydrophilic
molecules [55], medicinal chemists are still in search of an
algorithm to engineer uptake of biochemically identified
enzyme inhibitors [9]. In addition, intracellular uptake of
several drug classes is further reduced in non-replicating
mycobacteria [56]. Thus, fragments may have multiple
advantages over larger molecules: favourable absorption
and systemic PK properties, favourable tissue distribution,www.sciencedirect.com
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replicating bacilli. Whole cell screens of fragment libraries
against replicating and dormant mycobacteria would lever-
age these advantages, and deliver higher rates of quality
hits with attractive multi-target MoAs and PK properties.
Importantly, they would capture prodrugs and anti-metab-
olites requiring bio-activation inside the TB bacillus. This
would undoubtedly reduce the headaches of drug hunters
and their use of aspirin, which is perhaps one of the oldest
and most widely used multi-target, reactive fragment drugs
in the history of chemotherapy since 1897, with about 100
billion tablets swallowed each year [57].
Conclusion
Reactive multi-target fragments, old unusual antibacter-
ials, represent critical components of TB chemotherapies.
Studies of their MoA have revealed new concepts and
new targets for antimycobacterial drug discovery. Despite
recent progress, the MoA of PZA, the key relapse-
reducing drug, remains elusive. Understanding PZA
might provide the key to rational approaches to short-
ening TB chemotherapy. The success of dirty TB frag-
ment drugs suggests that fragment-based whole cell
screens, currently not part of mainstream drug discovery
efforts, should be included in antimicrobial discovery
activities for TB. Fragments might have mechanistic
advantages by being promiscuous binders and substrates,
and using ‘systems biology’ to kill [53]. Importantly, they
have attractive systemic and cellular (bacterial) PK prop-
erties (Figure 2). Interestingly, an old multi-purpose,
reactive multi-target fragment, dimethylfumarate, just
found a new career in multiple sclerosis treatment (0.5
billion USD in first quarter 2014) after showing a signifi-
cant effect on relapse rate in phase III clinical trials [58].
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